Jamal Siddiqui, MD
Ophthalmology · Tulsa, OKNPI 1578883336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 30.1% of the total. Among ophthalmology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$1K
- Sight Sciences, Inc.$550
- Bausch & Lomb Americas Inc.$526
- Sun Pharmaceutical Industries Inc.$474
- Tarsus Pharmaceuticals, Inc.$408
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$7,11899%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $2,151 |
| Alcon | 37 | $1,153 |
| Sight Sciences, Inc. | 19 | $550 |
| Bausch & Lomb Americas Inc. | 14 | $526 |
| Sun Pharmaceutical Industries Inc. | 17 | $474 |
| Tarsus Pharmaceuticals, Inc. | 16 | $408 |
| The Cameron-ehlen Group, Inc. | 3 | $361 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $231 |
| Rxsight Inc | 4 | $217 |
| Novartis | 10 | $185 |
| Recordati_rare_diseases_inc. | 4 | $181 |
| Ocular Therapeutix, Inc. | 6 | $149 |
| Glaukos Corporation | 2 | $105 |
| NEW World Medical,inc. | 1 | $99 |
| Aerie Pharmaceuticals, Inc. | 3 | $61 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $59 |
| Harrow Eye, LLC | 3 | $54 |
| Apellis Pharmaceuticals, Inc. | 2 | $34 |
| Oyster Point Pharma, Inc. | 2 | $29 |
| Dompe US, Inc. | 1 | $29 |
| Leadiant Biosciences, Inc. | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Thea Pharma Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$360
- Hydrus Microstent$249
- enVista MX60 IOL$240
- Tecnis Simplicity$222
- OMNI$213
- MIEBO$211
- Hydrus$146
- AcrySof IQ PanOptix UV IOL$146
- AcrySof IQ VIVITY$146
- CEQUA$128
- XELPROS$128
- XEN$125
- CYSTADROPS$125
- RXSIGHT INJECTOR HANDPIECE$124
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$124
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$124
- RXSIGHT INJECTOR CARTRIDGE$124
- RXSIGHT CONTACT LENS$124
- XDEMVY$122
- enVista Aspire IOL$120
How this compares
$7,157 in reported general payments places this provider in the 90th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 65 | $62,996 |
| XiidraLifitegrast | 19 | $34,336 |
| Prednisolone Acetate | 541 | $26,705 |
| TyrvayaVarenicline Tartrate | 15 | $11,710 |
| Ketorolac Tromethamine | 551 | $11,548 |
| LumiganBimatoprost | 18 | $9,967 |
| Ofloxacin | 569 | $6,497 |
| Latanoprost | 381 | $5,277 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,171 |
| Timolol Maleate | 64 | $763 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $683 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 57 | $594 |
| Brimonidine Tartrate | 31 | $402 |
| ErythromycinErythromycin Base | 32 | $364 |
| Acyclovir | 13 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $2,151 | $72,96383 claims |
| Bausch & Lomb Americas Inc.Xiidra | $526 | $34,33619 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $29 | $11,71015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Tulsa
- Shehzad BatliwalaTulsa$11K
- Thomas FinleyTulsa$9K
- Kelli DyerTulsa$6K
- Lars FreisbergTulsa$6K
- Neha SangalTulsa$5K
- Thomas BriggsTulsa$4K
- Marc GoldbergTulsa$4K
- Daniel LangleyTulsa$3K
- Mark AllisonTulsa$3K
- Justin ParschauerTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.